TIL Instil Bio, Inc.: רווח נקי למניה (EPS TTM)

Instil Bio, Inc. (TIL) positions are weakening due to stringent regulatory pressure and a capital deficit. Net income per share over the trailing 12 months visualizes these risks, where the value of -4.49 corresponds to the current metric. The company's success is based on clinical test data amid patent wars, while the reliability of treatment relies on flawless cryogenic cell transportation.

Net income per share over 12 months measures real equity income, stripping the financial result of the impact of issuance volume to assess the sustainability of the business model. By analyzing the 12-month earnings per share history, an investor can see how the inelastic demand for the unique cell therapy of Instil Bio, Inc. (TIL) converts into the fundamental value of each security, confirming the company's pricing power.